Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q99741
UPID:
CDC6_HUMAN
Alternative names:
CDC6-related protein; Cdc18-related protein; p62(cdc6)
Alternative UPACC:
Q99741; Q8TB30
Background:
Cell division control protein 6 homolog, known by alternative names such as CDC6-related protein, Cdc18-related protein, and p62(cdc6), plays a pivotal role in the initiation of DNA replication. It is also integral to checkpoint controls that ensure DNA replication is completed before mitosis is initiated, highlighting its critical function in cell cycle regulation.
Therapeutic significance:
Linked to Meier-Gorlin syndrome 5, a condition characterized by growth retardation, skeletal anomalies, and microcephaly, yet with normal intellect, the protein's gene variants suggest a therapeutic target. Understanding the role of Cell division control protein 6 homolog could open doors to potential therapeutic strategies for this syndrome.